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Background: The incidence of type 1 diabetes has increased worldwide, particularly in younger children and those
with lower genetic susceptibility. These observations suggest factors in the modern environment promote
pancreatic islet autoimmunity and destruction of insulin-producing beta cells. The Environmental Determinants of
Islet Autoimmunity (ENDIA) Study is investigating candidate environmental exposures and gene-environment
interactions that may contribute to the development of islet autoimmunity and type 1 diabetes.
Methods/design: ENDIA is the only prospective pregnancy/birth cohort study in the Southern Hemisphere
investigating the determinants of type 1 diabetes in at-risk children. The study will recruit 1,400 unborn infants or
infants less than six months of age with a first-degree relative (i.e. mother, father or sibling) with type 1 diabetes,
across five Australian states. Pregnant mothers/infants will be followed prospectively from early pregnancy through
childhood to investigate relationships between genotype, the development of islet autoimmunity (and
subsequently type 1 diabetes), and prenatal and postnatal environmental factors. ENDIA will evaluate the
microbiome, nutrition, bodyweight/composition, metabolome-lipidome, insulin resistance, innate and adaptive
immune function and viral infections. A systems biology approach will be used to integrate these data. Investigation will
be by 3-monthly assessments of the mother during pregnancy, then 3-monthly assessments of the child until
24 months of age and 6-monthly thereafter. The primary outcome measure is persistent islet autoimmunity, defined
as the presence of autoantibodies to one or more islet autoantigens on consecutive tests.
Discussion: Defining gene-environment interactions that initiate and/or promote destruction of the
insulin-producing beta cells in early life will inform approaches to primary prevention of type 1 diabetes. The
strength of ENDIA is the prospective, comprehensive and frequent systems-wide profiling from early pregnancy
through to early childhood, to capture dynamic environmental exposures that may shape the development of
islet autoimmunity.
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The rising incidence of T1D and gene-environment
interaction
Type 1 diabetes (T1D), one of the most common child
hood-onset chronic diseases, is associated with enor-
mous human and economic costs. The incidence of T1D
is increasing worldwide [1] with a younger age of onset
described in European and Australian populations [2,3].
In the 1980s the mean adjusted incidence rate of T1D in
Australia was ~11 per 100,000 person-years [4,5]. By 2006,
this had increased to 21.7 per 100,000 person-years, with
a 4.1% increase in the diagnosis of children less than
15 years of age from 1999 to 2006 [3].
The doubling in incidence of T1D in Australia over the
past two decades is consistent with a major role for the
modern environment in T1D pathogenesis. International
evidence to support this includes: (a) the reduced relative
frequency of high risk genotypes in newly diagnosed chil-
dren; (b) a less than 40% concordance of T1D in monozy-
gotic twins; (c) discrepancies in disease incidence among
genetically similar populations living in different regions,
and (d) migration studies that show T1D incidence in-
creases as populations move from low-risk to high-risk
areas [6].
The HLA region on chromosome 6p contributes ap-
proximately half of the genetic susceptibility to T1D, yet
the relative frequency of high risk HLA class II genotypes
in children presenting with T1D has decreased as the inci-
dence of the disease has increased [7]. Moreover, the rec-
ognition that over 60 gene loci are associated with T1D
has led to speculation that T1D is a disease with discrete
genetic subtypes whereby susceptibility genes interact dif-
ferently with environmental exposures [8]. Variation in
gene-environment interactions may explain different ef-
fects of environmental exposures in different populations
at-risk of T1D. For example, caesarean section increases
the risk of progression from islet autoimmunity to T1D
in individuals with T1D susceptible IFIH1 genotypes [9],
whereas the early introduction of cow’s milk may increase
risk of islet autoimmunity only in some at-risk genotypes
[10]. As the immunological processes associated with the
development of islet autoantibodies and T1D occur months
to years prior to the onset of clinical disease, a long asymp-
tomatic period provides the opportunity for prediction and,
potentially, prevention [11].
Prospective studies, including our own, reveal the de-
velopment of islet autoimmunity may occur at any point
during the first years of life [12] through to adolescence
[13], although recent data pooled from three large inter-
national cohorts have indicated the median age at serocon-
version is 2.1 years [14]. Once persistent islet autoimmunity
has developed the risk of progressing to T1D by 15 years of
age is 12.7% in children with a single islet autoantibody,
61.6% in children with two islet autoantibodies and 79.1%in children with three islet autoantibodies compared with
a 0.4% risk in children with no islet autoantibodies [14].
Moreover, progression to T1D is faster in children who: (a)
seroconvert prior to three years of age, (b) have human
leukocyte antigen (HLA) genotype DR3/DR4-DQ8, and (c)
are female [14].
The aim of the Environmental Determinants of Islet
Autoimmunity (ENDIA) study is to identify environmental
factors, and gene-environment interactions, that contribute
to and protect against the development of islet autoimmun-
ity and progression to T1D in children genetically at-risk of
T1D. We will follow 1,400 infants with a first-degree rela-
tive (FDR) with T1D prospectively from early pregnancy
into childhood to investigate relationships between prenatal
and postnatal environmental factors, and the development
of islet autoimmunity and subsequent T1D. ENDIA will
evaluate the microbiome, nutrition, bodyweight/compo-
sition, metabolome-lipidome, insulin resistance, innate and
adaptive immune function and viral infections. A systems
biology approach will integrate multi-omics analyses to ex-
plore hypotheses and mechanisms underlying the develop-
ment of islet autoimmunity.
The microbiome and islet autoimmunity
Contributors to aberrant development of the microbiome
Humans live in a symbiotic relationship with trillions of
microorganisms collectively known as the commensal
microbiome [15]. The establishment of the microbiome
begins at birth when the neonate is exposed to microor-
ganisms derived from the mother and immediate environ-
ment [16]. The composition of the microbiome changes
rapidly during early life until it is similar to that of an adult
by two years of age [17].
Several environmental factors contribute to shaping the
composition of microbiome including genotype, mode of
delivery, antibiotic use and microbial exposure in early life,
time of first fever, nutrition and weight gain in early life
[18,19]. Equally, contemporary changes in these factors
have also been linked to T1D. For example, the proportion
of Australian deliveries by caesarean section has increased
from 21% in 1998 to 31% in 2007 [20]. Vaginally delivered
infants acquire bacterial communities resembling their
own mother’s vaginal microbiome whereas infants deliv-
ered by caesarean section harbour communities similar to
those found on the skin [16]. This change in the initial
microbiome may lead to alternative microbial succession
patterns that persist over time and contribute to variations
in normal physiology and/or to disease risk [16]. A meta-
analysis of international observational studies showed a
20% increase in the incidence of T1D in children delivered
by caesarean section [17]. As a second example, the preva-
lence of overweight and obesity, currently at 34-50% [21]
in pregnancy and 27% [22] in childhood in Australia, has
increased over the last 20 years. With excessive weight
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the mother’s breast milk, which in turn impacts upon the
microbiome of the infant [17]. Early childhood weight gain
is associated with an increased risk of islet autoimmunity
[12] while childhood obesity is preceded by lower counts
of Bifidobacterium at six and 12 months of age [17]. Fi-
nally, antibiotic use, which has a direct effect on the gut
microbiome [18], has increased in children aged over two
in the last 10 years in Australia, although data during the
first two years of life are lacking [20].
The gut microbiome and host immune system
The development of the mucosal immune system, and
maturation of the systemic immune system, depends on
bacterial colonisation of the mucosa [23]. A normal muco-
sal immune system is necessary to generate regulatory T
cells (Treg) in response to oral antigens [24]. The essential
role of the mucosal immune system in maintaining im-
mune homeostasis is illustrated by the effect of a germ-free
versus a conventional ‘dirty’ environment on the incidence
of spontaneous autoimmune diabetes in the non-obese
diabetic (NOD) mouse, the best animal model of T1D. The
incidence of spontaneous diabetes in NOD mice differs
greatly between colonies around the world and is inverse-
ly correlated with exposure to microbial infection [25].
The high incidence of diabetes in NOD mice housed under
pathogen-free conditions is reduced by conventional con-
ditions of housing and feeding [26,27]. Under ‘dirty’ condi-
tions, bacterial colonisation of the intestine is accompanied
by maturation of mucosal immune function [28]. Emerging
evidence indicates that the gut microbiome differs in com-
position and function between children at risk for T1D
and case controls [29]. Supplementary to the microbiome,
breast milk contains growth factors, cytokines and other
immunomodulatory agents that promote functional matur-
ation of the intestinal mucosa and mucosal immune sys-
tem. Breast milk also contains endogenous insulin [30],
probably the key autoantigen in T1D [31], and ‘oral toler-
ance’ to insulin conceivably might protect against the de-
velopment of T1D.
Changes in the gut microbiome associated with islet
autoimmunity and T1D
Experimental diabetes models show that specific bacteria
and their products program Treg and T helper-17 (Th17)
cell development [32]. However, it is yet to be confirmed
if and how human gut microbes contribute to the devel-
opment of islet autoimmunity. Two small European stud-
ies involving a total of 17 children with islet autoimmunity
and 17 age/gender/HLA genotype matched controls re-
ported decreased microbial diversity in stools from chil-
dren with islet autoimmunity [33,34], while metagenomic
analysis revealed that children with islet autoimmunity
have less butyrate-producing and mucin-degrading bacteria[35]. This has led to speculation that the normal process
during the first two years of life by which a healthy mi-
crobiome becomes more diverse and stable, is not seen in
children who develop islet autoimmunity and T1D. Socio-
economic and cultural factors may play a role in shaping
the diversity of the microbiome. For example, the incidence
of T1D in Finland is 41.4 per 100,000 people per year, yet
in neighbouring Russian Karelia it is only 7.4 per 100,000
people per year, despite these populations sharing a genet-
ically similar background [36]. Karelian children show sig-
nificantly higher infection rates than their Finnish peers,
which alters the composition of the gut microbiome [37].
The challenge is to determine how these alterations relate
to the pathogenesis of T1D.
Therapeutic implications of the microbiome for T1D
If the microbiome is shaped by the early environment
and if specific changes in the microbiome are associated
with susceptibility to T1D, then in theory it should be
possible to re-engineer the microbiome and reduce the
incidence of T1D. This might be achieved in several ways,
for example by reducing the frequency of caesarean births,
avoiding unnecessary administration of antibiotics, promot-
ing breast feeding, modifying the early infant diet, avoiding
excessive weight gain and administering pre- and pro-
biotics. Administration of probiotics to NOD mice has been
shown to reduce their incidence of spontaneous auto-
immune diabetes [38].
Effects of weight gain on the development of islet
autoimmunity and T1D
Pregnancy weight gain and perinatal risk factors
influencing islet autoimmunity
In a retrospective study, higher maternal body mass index
(BMI) before pregnancy and weight gain >15 kg during
pregnancy predicted risk of islet autoimmunity in off-
spring with the high-risk HLA genotype, DR4-DQ8/DR3-
DQ2 [39]. No prospective data during pregnancy have
been published, however, perinatal risk factors have been
analysed in the German BabyDiab Study. Birth weight in
the middle tertile (3,250-3,700 g) was associated with in-
creased islet autoimmunity risk, as was maternal HbA1c
greater than 7% [40]. The presence of islet autoantibodies
in cord blood may also be a marker of reduced risk for
T1D in offspring [41,42].
Weight gain and nutrition during childhood
The rise in childhood incidence of T1D parallels the over-
weight/obesity epidemic in Western childhood populations.
Some evidence exists for an effect of early childhood weight
gain on risk of islet autoimmunity. In the first Australian
birth cohort of at-risk children (Australian BabyDiab study)
weight z-score and body mass index (BMI) z-score were
continuous predictors of risk of islet autoimmunity [12].
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in the Young (DAISY) birth cohort followed in Colorado,
height velocity from age two was associated with risk of
islet autoimmunity [43]. However, children in the German
BabyDiab cohort showed no effect of weight gain on risk
of islet autoimmunity [44]. Younger age of T1D onset is
inconsistently associated with higher BMI at diagnosis
[45,46]. Retrospective case control studies from Scandi-
navia link increased linear growth and weight gain in early
childhood with T1D [47].
Prospective birth cohorts show mixed data on the dur-
ation of exclusive breastfeeding and effect of solid food
exposure on risk of islet autoimmunity [48-54]. An early
analysis from the Trial to Reduce IDDM in the Genetic-
ally at-Risk (TRIGR) study suggests that feeding a casein
hydrolysate formula to Finnish infants at-risk of T1D fol-
lowing cessation of breastfeeding reduced risk of islet au-
toimmunity [55]. Recent evidence from the DIASY study
shows that both early and late first exposure to any solid
food predicts development of T1D, leading to speculation
that early exposure to solid foods evokes an abnormal re-
sponse in the immature gut; while late exposures may relate
to the cessation of breastfeeding before solid foods intro-
duction so that the protective effects of breast milk are lost
before the introduction of foreign food antigens [56].
Links between weight gain, systemic inflammation and
insulin resistance
Weight gain is associated with markers of innate immune
system activation and chronic low-grade inflammation,
which have been linked to insulin resistance. Previous stud-
ies have shown that pro-inflammatory CD11c + adipose tis-
sue macrophages impair insulin-stimulated glucose uptake
by human adipocytes, providing a possible mechanistic link
between obesity and insulin resistance [57]. In addition, adi-
pose tissue macrophages metabolize lipid and may initiate
adaptive immune responses by adipose tissue T cells, which
are activated in adipose tissue in obesity. Infants born small
for gestational age with catch up growth have accelerated
weight gain and insulin resistance in early life. Appropriate
for gestational age but premature babies also have reduced
insulin sensitivity [58]. The mechanism is unknown but un-
derscores the importance of prospective studies from preg-
nancy in at-risk children.
Innate and adaptive immune function and risk of islet
autoimmunity and T1D
Pro-inflammatory mediators and anti-inflammatory dietary
components in T1D
Circulating pro-inflammatory cytokines are increased at di-
agnosis in T1D [59-61] and, in a nested case–control study
of 67 children enrolled in the Viruses in the Genetically
at Risk (VIGR) birth cohort study (27 with islet antoanti-
bodies; 40 age-matched antibody negative controls), pro-inflammatory cytokines and chemokines were increased in
children with islet autoimmunity [62]. Whilst longitudinal
studies before diagnosis are lacking, the DAISY Study found
that serum C-reactive protein concentrations predicted pro-
gression to islet autoimmunity in early childhood [63].
Chronic low-grade inflammation in the mother has been
linked to insulin resistance in the offspring. Thus, concen-
trations of serum pro-inflammatory advanced glycation end
products (AGEs) at the end of healthy pregnancies were
associated with lower adiponectin and higher insulin levels
in the offspring [64]. We will measure both AGEs in preg-
nancy and AGEs and adiponectin in the offspring in
ENDIA.
The omega-3 fatty acids docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) reduce inflammatory cy-
tokines and inflammatory prostaglandins, both of which
contribute to the initial islet lesion. Accordingly, higher in-
take of DHA and EPA might lower the risk of T1D, but
definite evidence is lacking. Cod liver oil, omega-3 fatty
acids and vitamin D taken during pregnancy or infancy
have been associated with a lower incidence of T1D in a
case control study [65] and increased dietary omega-3 fatty
acid intake in infancy is weakly associated with a lower risk
of islet autoimmunity [66]. Therefore, protective effects of
these natural anti-inflammatory dietary components may
occur during pregnancy, during infancy, or both. DHA and
EPA inhibit prostaglandin E2 (PGE2) synthase with equiva-
lent or greater potency than other fatty acid analogues.
Vitamin D is an anti-inflammatory steroid with multiple
immunomodulatory effects that promotes immune toler-
ance. The vitamin D receptor (VDR) is expressed by all cells
of the immune system, while activated macrophages and
dendritic cells express 1α hydroxylase, the enzyme that con-
verts 25-hydroxyvitamin D3 (25 OHD) to its metabolically
active form, 1,25 OHD. Polymorphisms in both the VDR
and the gene that encodes 1α hydroxylase, CYP27B1 are as-
sociated with T1D risk [67-69]. Two Northern European
cross-sectional studies have shown an inverse relationship
between vitamin D supplementation in infancy and T1D in-
cidence [65,70], but the DAISY Study found no relationship
between 25 OHD levels and risk of islet autoimmunity or
progression to T1D [71]. Population 25 OHD levels have
fallen over the last 50 years with urbanisation, avoidance of
or less access to sunlight, decreased intake of oily fish and a
lower recommended daily intake of vitamin D. In Australia,
vitamin D insufficiency is common in pregnancy [72].
Adaptive immune function
Aberrant immune responses to self-antigens are con-
trolled by tolerance mechanisms, including suppression
by Treg cells. The impaired generation or function of Treg
cells, or resistance to their action, could contribute to the
development of autoimmune disease [73]. Indeed, an im-
balance between Treg and effector T cells has been linked
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mus during development and induced CD4+ Treg (iTreg)
by ‘tolerogenic’ conditions of antigen presentation postna-
tally in the periphery, especially in the mucosa. The micro-
biome is essential for development of the mucosal immune
system, which in turn is required for the generation of
iTreg. Treg are defined by high expression of CD25 and
stable expression of the transcription factor FOXP3, which
is critical to maintain expression of genes required for sup-
pressor function and prevent expression of genes required
for effector function [75]. FOXP3 is also expressed transi-
ently by activated T cells but its stable expression in Treg
is associated with demethylation at the FOXP3 locus. We
have identified another marker of stable Treg, namely pep-
tidase inhibitor 16 (CD359), which will be used to enumer-
ate Treg in the ENDIA Study [75].
In addition to conventional Treg, we have identified a
sub-population of CD4+ T cells with antigen-activated
suppressor function that are required to prevent auto-
immune diabetes in the NOD mouse model of T1D [76].
These cells are characterised by high expression of CD52
and exert suppression by releasing soluble CD52, which li-
gates inhibitory Siglec receptors. We observed that the fre-
quency and function of CD52hi CD4+ T cells in response
to the islet autoantigen, glutamic acid decarboxylase 65
(GAD65), was impaired in children at risk for T1D [76].
The characterisation of islet autoantigen-specific T cells,
including CD52hi CD4+ T cells, will be a critical compo-
nent of the ENDIA Study.
Enhanced innate immunity promoted by the environ-
ment may drive adaptive immunity by impairing regula-
tory and stimulating pathogenic T cell immunity. In the
ENDIA Study, we will measure cytokines and chemokines
produced in whole blood in vitro in response to innate im-
mune (TLR agonists) stimuli and adaptive immune (islet
[proinsulin, GAD65] and control [childhood vaccines]) an-
tigens [77].
Viral infection is associated with islet autoimmunity and T1D
Viruses might trigger the onset of islet autoimmunity
and/or promote the progression of established islet auto-
immunity. Prospective studies from birth are required to
obtain evidence in support of these possibilities; direct
proof of a causal role for viruses will be much harder to
obtain. In a meta-analysis, we recently reported evidence
for a role for enterovirus (EV) at the clinical onset of
T1D [78], with an odds ratio (OR) ~10 for EV infection
[79]. We have also found a significant association be-
tween EV infection and islet autoimmunity [78], with an
OR of ~4 in children with EV infection. Data on the role
of EV infection as an initiator [80,81] or accelerator [82] of
islet autoimmunity in longitudinal studies of genetically-
predisposed children are conflicting, although some of
these differences may be related to the use of differenttechniques for determining EV infection. The temporal re-
lationship between EV infection and development of islet
autoimmunity needs to established, as well as the inter-
action between EV infection and other environmental de-
terminants. For example, it has been reported that the
effect of EV infection on the development of islet auto-
immunity may be increased by early exposure to cow’s
milk [83]. In particular, the effect of maternal exposure to
the virus prenatally and of breastfeeding duration has not
been examined. We found that EV infection is more fre-
quent in recent-onset T1D in patients with co-existing
vitamin D deficiency (unpublished data).
Rotavirus (RV) infection, the most common cause of
infant diarrhoea, has been associated temporally with the
first appearance of islet autoantibodies [84], and molecular
mimicry has been demonstrated between human T cell
epitopes in RV and pancreatic islet autoantigens [85]. The
live RV vaccines RotaRix (GlaxoSmithKline) and RotaTeq
(Merck/CSL) are now available to all Australian infants
aged 6–32 weeks, with a 2008–2009 uptake rate of >80%
[86] compared with <50% in US [87]. It will therefore be
important to document if RV immunization alters the de-
velopment of islet autoimmunity and T1D incidence. The
lack of direct evidence for viral infection in causing T1D
is partly methodological but also suggests multiple other
and possibly ubiquitous environmental factors are at play.
Omics studies in the development of islet autoimmunity
and T1D
One of the challenges for interventional studies to pre-
vent T1D is a lack of biomarkers that reliably correlate
with disease activity. Consequently, study endpoints are
limited to assessments of beta-cell function and/or diagno-
sis of T1D following months to years of intervention [74].
Changes in the dynamic metabolome, lipidome and/or
proteome may provide suitable and sensitive biomarkers,
whilst providing insight into the underlying mechanisms
that initiate autoimmunity. For example, reduced levels
of succinic acid at birth and reduced phospholipids and
triglycerides in childhood, as measured within the blood
metabolome, were reported to precede islet autoimmunity
in children who progressed to T1D [88]. The same study
also identified elevated serum glutamic acid prior to the
appearance of GAD autoantibodies, leading to speculation
that an increased glutamate load on the beta cells may in-
crease activity of GAD65, a major beta-cell antigen, poten-
tially triggering the autoimmune process. More recently,
children who later developed islet autoimmunity and prog-
ressed to T1D were shown to have a distinct cord blood
lipidomic profile with reduced major choline-containing
phospholipids, implicating choline metabolism in preg-
nancy as a factor associated with progression to T1D,
although not necessarily with development of islet auto-
immunity per se [89].
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template by chemical and other epigenetic changes. An
epigenome-wide association study (EWAS) of DNA methy-
lation profiles of purified CD14+ monocytes (an immune
effector cell type relevant to T1D pathogenesis) from 15
pairs of monozygous twins discordant for T1D revealed
132 CpG sites that were differentially methylated in accord-
ance with T1D status [90]. By genome-wide methylation
analysis of human T cell subsets we identified previously
unrecognised hypomethylated promoter regions regulated
by FOXP3 in natural Treg [91]. Importantly, significantly
less methylation was observed in many of these gene pro-
moters in Treg from children with islet autoantibodies
compared to healthy controls, pointing to widespread alter-
ations in the epigenetic landscape. The ENDIA Study will
allow the epigenetic landscape to be scanned across time.
ENDIA in the context of international studies
investigating the environment and T1D risk
To our knowledge there are no other studies in the
Southern Hemisphere or South-East Asia investigating en-
vironmental determinants of T1D from pregnancy through
early life. Internationally, the ENDIA Study will differ from
The Environmental Determinants of Diabetes in the Young
(TEDDY) [92], the TRIGR [93] and German BabyDiab [94]
studies in that:
 ENDIA includes children on the basis of family
history, irrespective of HLA genotype. This is
relevant as the rising incidence of T1D is accounted
for by individuals with lower risk HLA genotypes.
 Prospective samples will be collected for analysis of
the microbiome from the gut (represented by stool),
oral cavity, nares, skin and vagina during pregnancy
and from breast milk during lactation (including
colostrum) and 3-monthly in early childhood.
Pregnancy and the first two years of life are critical
periods for the development and establishment of
the microbiota, underscoring the importance of
prospective studies from pregnancy.
 Nutritional status and intake will be documented
prospectively during pregnancy (from the first
trimester) and lactation [95].
 Weight gain and physical activity (using validated tools
[96]) will be measured prospectively during pregnancy.
 Nutritional status and intake in childhood will be
documented by daily diary until weaning and then
by multi-pass 24-h food recalls [97,98] until
24 months, and from two years by the Australian
Toddler Eating Survey [99].
 Fasting blood samples will be collected in childhood
to measure insulin resistance.
 The Australian population differs in many ways
from those in the USA and Europe, e.g. in diet, UVexposure, and immunisation status (Australia has a
much higher RV vaccine uptake than in USA).
Hypothesis and objectives
Hypotheses
The unifying hypothesis is that gene-environment inter-
actions during prenatal and postnatal development drive
the development of islet autoimmunity and T1D in chil-
dren at-risk for T1D.
The specific hypotheses are:
1. The maternal microbiome during pregnancy and
lactation differs in composition, diversity and
functional products between mothers whose offspring
do and do not develop islet autoimmunity and T1D.
2. The microbiome differs in composition, diversity
and functional products in children who do and do
not develop islet autoimmunity and T1D during the
first three years of life.
3. Accelerated weight gain during pregnancy, and
accelerated weight gain and insulin resistance during
the first three years of life, is associated with an
increased risk of islet autoimmunity.
4. Viral infection during pregnancy and first three years of
life modifies the risk of islet autoimmunity and T1D.
Objectives
1. To follow 1,400 children who have a first-degree
relative (FDR) with T1D during pregnancy and early
life to determine HLA genotype together with
multiple susceptibility genes, changes in the
microbiome, weight gain, metabolome-lipidome,
insulin sensitivity, nutritional status, inflammatory
markers, the timing and frequency of viral
infections, and the relationships between genetic and
environmental determinants.
2. To determine the relationship between changes in the
microbiome and prenatal and postnatal exposures,
including weight gain, metabolome-lipidome, insulin
sensitivity, nutritional status, and viral infection, and
the development of persistent islet autoimmunity in
children with a FDR with T1D.
The long-term objective is to follow T1D at-risk chil-
dren into adolescence to determine the relationship be-
tween genotype, the microbiome and the environment,
and the development of islet autoimmunity and T1D.
Methods/design
Summary of design
This is a prospective cohort study of the offspring of
1,400 mothers who have T1D, or a FDR with T1D, from
pregnancy through childhood. Recruitment and consent
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as soon as feasible after the mother has given consent and
investigation is 3-monthly throughout the pregnancy. At
birth there is investigation of the mother and child and
the child is then followed 3-monthly for two years, and
6-monthly thereafter. The primary outcome measure is
persistent islet autoimmunity. The secondary outcome
measure is the development of T1D. An overview of the
study activities across time is shown in Table 1.
Estimation of target population
The population in the five states (New South Wales
(NSW), Western Australia (WA), Queensland (Qld),
Victoria (Vic) and South Australia (SA)) participating in
ENDIA is 20.8 million, i.e. ~92% of Australia’s total pop-
ulation, and of these 3,500,000 men and 3,500,000 women
aged 15–40 years [100]. Conservatively, there are 90,000
people with T1D in Australia, of whom ~15,000 are aged
0–14 years and ~45,000 aged 15–40 years, affecting men
and women equally. Therefore, the prevalence of T1D
among Australian women aged 15–40 years is 22,500/
3,500,000 or 0.6%. Every year 250,000 women give birth in
Australia, of whom 0.6% (n = 1,500) have T1D. There will
also be 1,500 new fathers each year with T1D. Thus, ap-
proximately 3,000 births annually are to a parent with
T1D. In contrast, the prevalence of siblings with T1D is
relatively low. The incidence of T1D in children aged 0–
14 is 22 per 100,000 person years [3]. Of 250,000 new-
borns each year in Australia, approximately half (125,000)
will have a sibling. If the majority of those have a sibling
aged 0–14 years, only ~28 will have T1D. Therefore, there
are approximately 3,000 potential participants per annum
of whom we aim to recruit 400–475 per year.
Determination of sample size
We estimate recruitment of 1,400 participants from the
five states over three years, followed for a median of two
years with a 9% rate of persistent islet autoimmunity.
Maximum total dropout /lost to follow-up rate is estimated
at 15% with the majority of dropouts occurring in the first
six months of follow-up. These estimates are based on data
from the Australian BabyDiab [12] and TRIGR [93] at-risk
birth cohorts in which dropout rates were 15% and 7%,
respectively.
Using nQuery Advisor, with 600 participants above the
median and 600 below (1200 total after 15% drop out
from 1,400), for a given exposure variable, power is 90%
to detect a difference between survival (i.e. no islet auto-
immunity) of 93% in one group and survival of 88% in
the other – with 108 events (islet autoimmunity) or 9%
of the total sample of 1,200 required [101]. For examin-
ing interactions between uncorrelated exposure variables
with approximately 375 participants per combination of
above/below the median, the power is 77% to detect adifference in survival (no islet autoimmunity) between
93% and 87% (70 events in 600 participants required).
Recruitment, retention and withdrawal of participants
Inclusion criteria
The inclusion criteria for ENDIA are an unborn child with
an FDR with T1D, targeting the mother for recruitment in
first, second or third trimester of pregnancy, or an infant
less than six months of age with a FDR with T1D.
Exclusion criteria
The only exclusion criterion is the incapacity for the preg-
nant woman (or in the case of postnatal recruitment, the
child’s primary caregiver) to understand the requirements
of her and/or her child’s participation. This may be due to
illiteracy, an intellectual disability or a mental illness.
Withdrawal criteria
Participants will be withdrawn from the study if they de-
velop T1D in the case of the child, or request to discon-
tinue participation in the case of the mother on behalf
of herself and the child. The reason for withdrawal from
the study will be captured on the case report form. Every
effort will be made to continue to follow all participants
enrolled in the study except for those who withdraw
consent. Participants who are withdrawn from the study
will be contacted by telephone annually to determine their
T1D status.
Recruitment
Participants will be identified during pregnancy or within
six months of birth in NSW, WA, Qld, Vic and SA. FDRs
will be mothers, fathers or siblings with T1D. Since major-
ity will be a mother or a father with T1D, pregnant women
with T1D or whose partner has T1D are the main focus of
recruitment. Eligible participants will be identified from
the following sources: (1) prospective mothers attending
public and private antenatal clinics prior to delivery, (2)
prospective parents attending public and private diabetes
clinics, (3) pregnant mothers of existing patients attending
paediatric diabetes clinics, (4) diabetes organisations, and
(5) local and national mainstream advertising.
Private endocrinologists and obstetricians known to
manage T1D in young adults will be targeted with visits
from research staff and personalised letters, brochures and
posters. Paediatric T1D clinics will recruit families in which
a sibling has T1D. Our research team includes endocrinol-
ogists and a perinatologist, all with substantial experience
in recruitment of participants during pregnancy.
State and national diabetes networks and advocacy
groups will be used to promote the study, as well as a ded-
icated website (http://www.endia.org.au) and social media
such as Facebook (https://www.facebook.com/endiastudy)
and Twitter. All advertising material, media releases and
Table 1 Study design overview




























Labour and delivery *ψ
Congenital abnormalities *ψ
Anthropometry - Height, Weight, BMI * * * *
Weight z, length z, BMI z * * * * *
Waist circumference * * * * *
Lifestyle questionnaire * * * * * * *
Blood A: Serum (red) AutoAbs: Melbourne * *Δ * * * *
AutoAbs: Adelaide * *Δ * * * *
Resistance: adiponectin, hsCRP,
C-peptide, insulin, glucose
* * * *Δ * * * *
Metabolome/lipidome * * * *Δ * * * *
















(12, 24, 36 m)
C: LH (green) Cytokines/chemokines
(innate immunity)
* * * *
D: K-EDTA (purple) Buffy coat (epigenome) * * * *Δ * * * *
RBC * * * *Δ * * * *
Virology * * * *ΔΩ * * * *
DHA, EPA, resolvins,
protectins, prostaglandin E2
* * * *Δ * *
Advanced glycation end
products

















Table 1 Study design overview (Continued)
Haemoglobin A1C (HbA1c) *†† *†† *†† *Δ *ϕ *ϕ
E: K-EDTA (purple) HLA typing *Δ *
F: CPT sodium citrate
(blue/black)
PBMCs (adaptive immunity) *Δ * * *
Urine Maternal: urine pot
Infant: collection bag
Metabolome/lipidome * * * * * * * *
Advanced glycation end
products
* * * * * *
Stool Maternal: EasySampler
Infant: stool collection kit
Microbiome * * * * * * * *
Virology * * * * * * * *
Metabolome/lipidome * * * * * * * *
Saliva Oragene kit SNP typing * *
Tongue dorsum ESwab swab Microbiome * * * * * * * *
Buccal mucosa ESwab swab Microbiome * * * * * * * *
Throat UTM Virology * * * * * * * *
Nasal ESwab swab Microbiome * * * * * * * *
Skin (inner elbows) ESwab swab Microbiome * * m&i * m&i * m&i * m&i * *
Vagina ESwab swab Microbiome *
Colostrum (day 0–3) Colostrum collection kit Microbiome *
Metabolome/lipidome *
Breast milk Milk collection kit Microbiome * *ζ *ζ *ζ *ζ
Metabolome/lipidome * *ζ *ζ *V3 ζ
Diet Maternal diet evaluation
tools
DQES version 2 * *ζ
Infant diet evaluation
tools
Infant diary (birth-6 m) * *
Infant diary (6-12 m) * V3 * V4
24 hour recall
(12 – 24 months)
* V5, V7 * V6
Australian Toddler Eating
Survey (>24 months)
* V9 * V8, V10
† if available.
ψ or at first opportunity.
†† if mother has T1D.
ϕ if persistent islet autoantibodies are detected.
Δ cord blood.
Ω using Guthrie Card if cord blood sample not taken.
“m&i” maternal and infant.
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proved by the relevant Human Research Ethics Commit-
tees in each state prior to distribution.
Participant retention
Our past experience indicates that families affected by T1D
are highly motivated to participate in research. The previ-
ous Australian BabyDiab birth cohort in SA and Victoria
recruited 548 children followed over a median of 5.7 years,
while the participant retention rate in the NSW arm of the
TRIGR study was 87% after five years (80% planned) [93].
This high rate is attributed to frequent family phone con-
tacts, newsletters, distribution of calendars with reminders
and incentives such as birthday cards, the set-up of parent’s
groups for T1D families and active assistance with surveil-
lance of the health of the participating child. Similar strat-
egies will be implemented in ENDIA.
Participant engagement in the study will be central to
high retention rates. More than half of people within the
target population (men and women aged 18–34) have a
Facebook page [102]. The site will be monitored daily and
updated regularly to maintain relevancy. We will also use
Facebook to link with existing T1D networks and advocacy
groups, including JDRF International, JDRF Australia and
Diabetes Australia, thereby generating further awareness
of the study.
Study activities
Pregnancy visits 1 and 2: first and second trimesters
The following will be undertaken before 13 weeks gesta-
tion and again before 26 weeks gestation:
 Documentation of maternal and paternal
demographics including medical and obstetric history
 Maternal anthropometry: height, weight, BMI
 Collection of blood sample for investigations defined
in Table 1
 Collection of nasal, buccal, tongue and throat swabs,
urine and stool specimens for microbiome studies
 Administration of the Pregnancy Lifestyle
Questionnaire and Pregnancy Physical Activity
Questionnaire [96]
 Documentation of proband history of T1D and
other significant medical history
 Blood and saliva will also be collected from the
proband on one occasion for HLA genotyping and
SNP analysis, respectively
Pregnancy visit 3: third trimester
Between 24 and 38 weeks gestation investigations will be
as for first/second trimester PLUS
 Documentation of results of the oral GTT, as
routinely performed in pregnancy Explanation by research nurse (trained by study
dietician) as to how to complete the DQES version 2
(DQESv2) questionnaire for nutrition analysis [95]
 Vaginal and skin swabs for analysis of the microbiome
 Documentation of pregnancy complications:
hypertension, preeclampsia, HELLP, hyperemesis
gravidarum
Birth and week 1 of life
The following will be undertaken across two study visits
within the first week of life. The first, termed the B1 visit,
will be within the first two days post-partum; the second,
termed the B2 visit, will be 3–5 days post-partum.
 Collection of cord blood samples for investigations
defined in Table 1
 Completion of the documentation of the pregnancy
complications, and /or of any congenital
abnormalities in the child
 Documentation of birth date, gestation, gender, birth
weight, placental weight, birth length, APGAR score,
method of delivery and any complications of the
birth, perinatal and neonatal periods
 Record of maternal weight gain during pregnancy
 Viral studies, including serology and qPCR, will be
performed from urine taken at B2 visit
 Collection of colostrum samples at B1 and B2 visits
for microbiome studies
 Collection of skin swabs from infant and mother B1
and B2 visits for microbiome studies
 Collection of meconium (first nappy) at B1 visit and
stool samples, nasal, buccal, tongue and throat swabs
from infant at B2 visit, all for microbiome studies
Follow-up visits at 3, 6, 9, 12, 15, 18, 21, 24, 30 and
36 months of age
The following will be performed once:
 Saliva sampling from the infant for SNP genotype
 Documentation of maternal nutrition during lactation
using the DQESv2 questionnaire at three months
The following will be undertaken at each visit:
 Collection of blood sample for investigations
outlined in Table 1. If a child develops persistent
islet autoimmunity, as defined above, HbA1c will be
also measured 6-monthly
 Anthropometrics: length (height at 30 and 36 months),
weight, BMI, waist circumference (at umbilicus)
 Collection of nasal, buccal, tongue, throat and skin
swabs and stool samples for microbiome studies
 Nutrition and Lifestyle assessments (Refer to
Additional file 1)
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investigations
A detailed description of the data collection, sampling pro-
cedures and laboratory investigations can be found in
Additional file 1. Data collection tools developed specific-
ally for the ENDIA Study evaluating infant feeing, mater-
nal lifestyle in pregnancy, and maternal/infant lifestyle
postpartum are provided in Additional files 2, 3 and 4,
respectively.
Analysis of the primary outcome measure
The primary outcome measure is islet autoimmunity de-
fined as elevation of ≥ one islet autoantibody on consecu-
tive tests. Time-to-event analyses will explore the effect of
variables on the risk of islet autoimmunity. Unadjusted
and adjusted Hazard Ratios (HR) will be calculated using
parametric and non-parametric (proportional hazard) sur-
vival models. The models will account for right censored
data due to variable length of follow up and loss of follow
up of participants. Variables measured over time (continu-
ous and categorical) will be entered into survival models
as time-dependent covariates as these measurements will
be repeatedly obtained from individual participants. Ad-
justed HRs will be used to analyse the development of islet
autoimmunity while controlling for associated variables as
we have described [12]. Viral infections will also be mod-
elled using survival analysis techniques. A fixed (time-
independent) covariate will be used to test for associations
with antenatal/postnatal viral infections/events, and time-
dependent variables will be constructed to indicate expo-
sure to viral infections throughout the follow-up period
for each child.
Logistic regression analysis will be used to compare the
relationship between presence or absence of islet auto-
immunity and other variables. For analysis of nested case
controls and longitudinal changes in the microbiome, islet
autoimmune and non-islet autoimmune participants will
be matched for age, gender, HLA type, ethnicity, proband
relationship, parity, mode of delivery and gestation/birth
weight.
A systems biology approach will be used to reveal inter-
relationships between prenatal and postnatal environmental
exposures that may condition the microbiome, metabolome
and epigenome – these include maternal T1D, nutrition,
weight gain, physical activity and viral infection during
pregnancy; and mode of delivery, accelerated weight gain,
nutrition, immune function, early fever, antibiotic use and
viral infection during early life.
Safety parameters
Ethics committee review
In accordance with the Australian National Statement
[103], in line with the ICH Guideline for Good Clinical
Practice, the investigators have obtained written approval ofthe study protocol and Participant Information and Con-
sent Form from the Human Research Ethics Committee
(HREC) prior to commencement of the study. The study
has been registered with the Australian New Zealand Clin-
ical Trials Registry (ANZCTR) with registration number
ACTRN12613000794707.Subject information and consent
As this study involves mothers and children aged less than
12 years, the mother will be invited to provide written con-
sent for herself and the child. The informed consent to par-
ticipate in the study must be obtained by the investigator,
or a person designated by the investigator, in accordance
with the ICH Guidelines for Good Clinical Practice. Writ-
ten informed consent will be obtained for the child using
the HREC approved Participant Information and Consent
Form. The parent/guardian will be advised in a timely man-
ner of any new information that may be relevant to their
willingness to participate.Monitoring
The Investigator(s)/institution(s) will permit study-related
monitoring, audits, HREC review, and direct access to case
record forms, source documents and study files at all study
sites for monitoring and audit purposes, at reasonable
times, during the course of the study and after completion.
The Project Manager will undertake an annual visit to at
all five study sites to review case record forms, source doc-
uments, sample storage and study files. The investigators
will participate in regular teleconferences and an annual
face-to-face meeting.Adverse event reporting
The investigators are responsible for conduct of the study
in accordance with GCP regulations, which includes the
recording and reporting of adverse events observed during
and after the study. For all adverse events, the severity, on-
set, duration, determination of seriousness, action taken,
any treatment given, outcome, and the investigator’s as-
sessment of the relationship to study procedure will be
recorded by the investigator. The most likely physical ad-
verse event will be related to venipuncture. Reaction to
venipuncture will be elicited by direct questioning of the
mother or the primary caregiver. There is also potential
for adverse psychological events associated with anxiety
and grief the parents are likely to feel if their child de-
velops islet autoimmunity. Each state has investigator(s)
experienced in counselling families about the significance
of islet autoimmunity and knowledgeable about the care
of children with T1D. The investigators have combined
experience in following over 1,000 children for the devel-
opment of islet autoimmunity over the last 20 years.
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Data protection and confidentiality
All provided biological samples will be labelled with a re-
identifiable study number. The electronic study informa-
tion will be stored in a dedicated, limited access clinical
registry developed by the Melbourne eResearch Group of
the University of Melbourne. The registry features elec-
tronic Case Report Forms and integrated electronic ques-
tionnaires for real-time data processing. Key capabilities
support for fine grained access control systems with strong
data encryption, secure data enclaves with advanced data
management as well as secure back-up of the data entered.
As such, the registry is compliant with international stan-
dards for electronic systems in clinical studies.Discussion
The central aim of the ENDIA Study is to identify the
gene-environment interactions occurring during prenatal
and/or postnatal development that drive the develop-
ment of islet autoimmunity and T1D in children genetic-
ally at-risk of T1D. Recruitment will begin prospectively
during pregnancy with 3-monthly follow-up until two years
of age then 6-monthly thereafter in an ongoing cohort
study. The cohort will be well characterised in terms of
demographics, maternal and proband medical history, ob-
stetric history, parturition and anthropometry. An in-depth
analysis of maternal and infant nutrition will inform a
comprehensive sampling strategy involving the longitudinal
collection of blood and DNA for immune and multi-omics
analyses, and stool, urine, breast milk, oral cavity, nares
and skin samples/swabs for microbiome analysis. The rapid
change of the microbiome after birth in relation to prenatal
and postnatal exposures, geographical variations and the
onset of islet autoimmunity before two years of age under-
scores the importance of studying the cohort from preg-
nancy into early childhood with frequent sampling during
the first two years of life, and analysis in relation to the en-
vironmental, cultural and genetic influences that are likely
to be relevant to an Australian population.
Defining modifiable host and environment factors that
initiate and/or promote destruction of insulin-producing
cells in early life will have enormous implications for in-
dividuals with and at risk of T1D and their families, and
for the health care system given the annual cost of approxi-
mately $5,000 per person with T1D in Australia [104]. In
the short term, outcome data generated from this study
aims to provide education programs for T1D risk reduc-
tion during pre-conception, pregnancy and early infancy
in families with children at risk. In the medium term, the
translation of data for gene-environment interactions may
allow testing of families for T1D susceptibility genes and
education about their relative risk of environmental factors
according to genotype. In the longer term, outcomes of theENDIA Study may lead to a means of primary prevention
of T1D before the autoimmune process begins.
Additional files
Additional file 1: A detailed description of the data collection,
sampling procedures and laboratory investigations employed in the
ENDIA study.
Additional file 2: The ENDIA Infant Feeding Diary developed for
this study.
Additional file 3: The ENDIA Maternal Lifestyle in Pregnancy
questionnaire developed for this study.
Additional file 4: The ENDIA Maternal/Infant Lifestyle Postpartum
questionnaire developed for this study.
Abbreviations
AGEs: Advanced glycation end products; BMI: Body mass index;
DHA: Docosahexaenoic acid; ENDIA: Environmental determinants of islet
autoimmunity; EPA: Eicosapentaenoic acid; EV: Enterovirus; FDR: First-degree
relative; GADAb: Glutamic acid decarboxylase 65 autoantibodies;
HLA: Human leukocyte antigen; IA2Ab: Tyrosine phosphatase-like insulinoma
antigen autoantibodies; IAA: Insulin autoantibodies; NOD: non-obese
diabetic; PGE2: Prostaglandin E2; RV: Rotavirus; T1D: Type 1 diabetes;
Treg: Regulatory T cell; tTGAb: Tissue transglutaminase autoantibodies;
ZnT8Ab: Beta cell-specific zinc transporter 8 autoantibodies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The ENDIA Study writing group is comprised of MP, JC, MC, PC, WR, AC, TJ
and LH. All assume responsibility for the production of this manuscript. The
study was conceived by JC and LH. The study was designed by JC, LH, MC,
PC and WR. The study Project Manager is MP. State Principal Investigators
are JC (SA), MC (NSW), TJ (WA), PC (Vic) and AC (Qld). PB is an additional
Principal Investigator. The Associated Investigators are FC, JD, MM, GM, AN
and JW. The Significant Collaborators are CD, JF, KN and RS. All authors have
read and approved the final manuscript.
Authors’ information
ENDIA Study Group:
Peter A Baghurst1, Simon C Barry2, Fergus J Cameron3, Jodie M Dodd4, Chris
Duran5, Josephine M Forbes6, Maria Makrides2,7, Grant Morahan8, Karen E
Nelson9, Alison J Nankervis10, Richard O Sinnott5, John M Wentworth11,12
1School of Population Health, University of Adelaide, Adelaide, SA 5005
2Discipline of Paediatrics, School of Paediatrics and Reproductive Health,
University of Adelaide, Adelaide, SA 5005
3Department of Endocrinology and Diabetes and Centre for Hormone
Research, Royal Children’s Hospital and Murdoch Children’s Research
Institute, Parkville, Victoria 3052
4School of Obstetrics and Gynaecology, University of Adelaide, Adelaide, SA 5005
5Department of Computing and Information Systems, University of
Melbourne, Parkville, Victoria 3010
6Mater Medical Research Institute, South Brisbane, Queensland 4101
7Women’s and Children’s Health Research Institute, King William Road, North
Adelaide, SA, 5006
8Centre for Diabetes Research, Western Australian Medical Research Institute,
Perth, WA 6000
9J. Craig Venter Institute, Rockville, MD 20850 USA
10Royal Women’s Hospital, Parkville, Victoria 3052
11Royal Melbourne Hospital, Parkville, Victoria 3050
12Walter and Eliza Hall Institute, Parkville, Victoria 3050
Acknowledgements
This study is funded by the Australian National Health and Medical Research
Council (NHMRC Project Grant 1025083). The authors wish to acknowledge
the contributions of A/Prof Karen Walker (Monash University), Ms Bronwen
D’Arcy (Women’s and Children’s Hospital), Dr Gilly Hendrie (CSIRO) and Prof
Penno et al. BMC Pediatrics 2013, 13:124 Page 13 of 15
http://www.biomedcentral.com/1471-2431/13/124Clare Collins (University of Newcastle) in the development of tools for
evaluating diet and nutrition. We also acknowledge the participation of Ms
Felicity Healy (Melbourne Health), Mr Wayne Soon (Princess Margaret
Hospital), Ms Sherrell Cardinal (Mater Health Service), and Ms Jacki Catteau
(Children’s Hospital at Westmead) for the preparation of documents for
ethics/research governance submissions and the local study coordinators.
Author details
1Discipline of Paediatrics, School of Paediatrics and Reproductive Health,
University of Adelaide, Adelaide, SA 5005, Australia. 2Endocrine and Diabetes
Department, Women’s and Children’s Hospital, North Adelaide, SA 5006,
Australia. 3Virology Division, Department of Microbiology, South Eastern Area
Laboratory Services, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
4School of Women’s and Children’s Health, University of New South Wales,
Sydney, NSW 2052, Australia. 5Institute of Endocrinology and Diabetes, The
Children’s Hospital at Westmead, Westmead, NSW 2145, Australia. 6Discipline
of Paediatrics and Child Health, University of Sydney, Sydney, NSW 2006,
Australia. 7Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. 8SOMS
Faculty of Medicine, and BABS Faculty of Science, University of New South
Wales, Sydney, NSW 2052, Australia. 9Mater Health Services, South Brisbane,
Queensland 4101, Australia. 10Princess Margaret Hospital Department of
Endocrinology and Diabetes, School of Paediatrics and Child Health;
Telethon Institute of Child Health Research, University of Western Australia,
Perth, WA 6008, Australia. 11Walter and Eliza Hall Institute, Parkville, Victoria
3050, Australia.
Received: 29 July 2013 Accepted: 12 August 2013
Published: 14 August 2013
References
1. Diamond Project Group: Incidence and trends of childhood type 1
diabetes worldwide 1990–1999. Diabet Med 2006, 23(8):857–866.
2. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G: Incidence trends
for childhood type 1 diabetes in Europe during 1989–2003 and
predicted new cases 2005–20: a multicentre prospective registration
study. Lancet 2009, 373(9680):2027–2033.
3. Catanzariti L, Faulks K, Moon L, Waters AM, Flack J, Craig ME: Australia’s
national trends in the incidence of type 1 diabetes in 0–14-year-olds,
2000–2006. Diabet Med 2009, 26(6):596–601.
4. Haynes A, Bower C, Bulsara MK, Jones TW, Davis EA: Continued increase in
the incidence of childhood type 1 diabetes in a population-based
Australian sample (1985–2002). Diabetologia 2004, 47(5):866–870.
5. Taplin CE, Craig ME, Lloyd M, Talyor C, Crock P, Silink M, Howard NJ: The
rising incidence of childhood type 1 diabetes in New South Wales,
1990–2002. Med J Aust 2005, 183(5):243–246.
6. Knip M: Pathogenesis of type 1 diabetes: implications for incidence
trends. Horm Res Paediatr 2011, 76(Suppl 1):57–64.
7. Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG,
Harrison LC: The rising incidence of type 1 diabetes is accounted for by
cases with lower-risk human leukocyte antigen genotypes. Diabetes Care
2008, 31(8):1546–1549.
8. Morahan G: Insights into type 1 diabetes provided by genetic analyses.
Curr Opin Endocrinol Diabetes Obes 2012, 19(4):263–270.
9. Bonifacio E, Warncke K, Winkler C, Wallner M, Ziegler AG: Cesarean section
and interferon-induced helicase gene polymorphisms combine to
increase childhood type 1 diabetes risk. Diabetes 2011, 60(12):3300–3306.
10. Lempainen J, Vaarala O, Makela M, Veijola R, Simell O, Knip M, Hermann R,
Ilonen J: Interplay between PTPN22 C1858T polymorphism and cow’s milk
formula exposure in type 1 diabetes. J Autoimmun 2009, 33(2):155–164.
11. Purohit S, She JX: Biomarkers for type 1 diabetes. Int J Clin Exp Med 2008,
1(2):98–116.
12. Couper JJ, Beresford S, Hirte C, Baghurst PA, Pollard A, Tait BD, Harrison LC,
Colman PG: Weight gain in early life predicts risk of islet autoimmunity
in children with a first-degree relative with type 1 diabetes. Diabetes Care
2009, 32(1):94–99.
13. Colman PG, McNair PD, Gellert S, Kewming K, Schmidli RS, Steele CE,
Harrison LC: Development of autoantibodies to islet antigens during
childhood: implications for preclinical type 1 diabetes screening.
Pediatr Diabetes 2002, 3(3):144–148.
14. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C,
Ilonen J, Veijola R, Knip M, et al: Seroconversion to multiple isletautoantibodies and risk of progression to diabetes in children. JAMA
2013, 309(23):2473–2479.
15. Littman DR, Pamer EG: Role of the commensal microbiota in normal and
pathogenic host immune responses. Cell Host Microbe 2011, 10(4):311–323.
16. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer
N, Knight R: Delivery mode shapes the acquisition and structure of the
initial microbiota across multiple body habitats in newborns. Proc Natl
Acad Sci U S A 2010, 107(26):11971–11975.
17. Isolauri E: Development of healthy gut microbiota early in life. J Paediatr
Child Health 2012, 48(Suppl 3):1–6.
18. Johnson CL, Versalovic J: The human microbiome and its potential
importance to pediatrics. Pediatrics 2012, 129(5):950–960.
19. Rigon G, Vallone C, Lucantoni V, Signore F: Maternal factors pre- and
during delivery contribute to gut microbiota shaping in newborns. Front
Cell Infect Microbiol 2012, 2:93.
20. Australian Institute for Health and Welfare 2011: Australia's welfare 2011.
In Australia’s welfare series. Volume 10, Cat. no. AUS 142. Canberra: Australian
Institute for Health and Welfare; 2011.
21. Kannieappan LM, Deussen AR, Grivell RM, Yelland L, Dodd JM: Developing
a tool for obtaining maternal skinfold thickness measurements and
assessing inter-observer variability among pregnant women who are
overweight and obese. BMC Pregnancy Childbirth 2013, 13(1):42.
22. Australian Government Department of Health and Aging: 2007 Australian
National Children’s Nutrition and Physical Activity Survey- Main Findings. http://
www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/
66596E8FC68FD1A3CA2574D50027DB86/$File/childrens-nut-phys-survey.pdf.
23. Macpherson AJ, Harris NL: Interactions between commensal intestinal
bacteria and the immune system. Nat Rev Immunol 2004, 4(6):478–485.
24. Locke NR, Stankovic S, Funda DP, Harrison LC: TCR gamma delta
intraepithelial lymphocytes are required for self-tolerance. J Immunol
2006, 176(11):6553–6559.
25. Pozzilli P, Signore A, Williams AJ, Beales PE: NOD mouse colonies around
the world–recent facts and figures. Immunol Today 1993, 14(5):193–196.
26. Suzuki T: Diabetogenic effects of lymphocyte transfusion on the NOD or
NOD nude mouse. In Immune deficient animals in biomedical research.
Edited by Rygaard J, Brunner N, Graem N, Spang-Thomson M. Basel: Karger;
1987:112–116.
27. Funda DP, Fundova P, Harrison LC: Environmental-mucosal interactions in
the natural history of type 1 diabetes: the germ-free (GF) NOD mouse
model. In Proceedings of the 7th Immunology of Diabetes Society Meeting.
vol. 41. Edited by Sanjeevi CB, Gale EAM. New York: Ann N Y Acad Sci; 2005.
28. Kawaguchi-Miyashita M, Shimizu K, Nanno M, Shimada S, Watanabe T, Koga Y,
Matsuoka Y, Ishikawa H, Hashimoto K, Ohwaki M: Development and cytolytic
function of intestinal intraepithelial T lymphocytes in antigen-minimized
mice. Immunology 1996, 89(2):268–273.
29. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N,
Casella G, Drew JC, Ilonen J, Knip M, et al: Gut microbiome metagenomics
analysis suggests a functional model for the development of autoimmunity
for type 1 diabetes. PLoS One 2011, 6:e25792.
30. Shehadeh N, Gelertner L, Blazer S, Perlman R, Etzioni A: The importance of
insulin content in infant diet: suggestion for a new infant formula
period. Acta Pediatr 2001, 90:93–95.
31. Narendran P, Mannering SI, Harrison LC: Proinsulin-a pathogenic
autoantigen in type 1 diabetes. Autoimmun Rev 2003, 2(4):204–210.
32. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC,
Santee CA, Lynch SV, et al: Induction of intestinal Th17 cells by segmented
filamentous bacteria. Cell 2009, 139(3):485–498.
33. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, Drew JC,
Ilonen J, Knip M, Hyoty H, et al: Toward defining the autoimmune
microbiome for type 1 diabetes. ISME J 2011, 5(1):82–91.
34. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T,
Orivuori L, Hakala S, Welling GW, Harmsen HJ, Vaarala O: Fecal microbiota
composition differs between children with beta-cell autoimmunity and
those without. Diabetes 2013, 62:1238–1244.
35. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N,
Casella G, Drew JC, Ilonen J, Knip M, et al: Gut microbiome metagenomics
analysis suggests a functional model for the development of autoimmunity
for type 1 diabetes. PLoS One 2011, 6(10):e25792.
36. Kondrashova A, Reunanen A, Romanov A, Karvonen A, Viskari H, Vesikari T,
Ilonen J, Knip M, Hyoty H: A six-fold gradient in the incidence of type 1
diabetes at the eastern border of Finland. Ann Med 2005, 37(1):67–72.
Penno et al. BMC Pediatrics 2013, 13:124 Page 14 of 15
http://www.biomedcentral.com/1471-2431/13/12437. Seiskari T, Kondrashova A, Viskari H, Kaila M, Haapala AM, Aittoniemi J, Virta M,
Hurme M, Uibo R, Knip M, et al: Allergic sensitization and microbial load–a
comparison between Finland and Russian Karelia. Clin Exp Immunol 2007,
148(1):47–52.
38. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB,
Ferretti E, Gulino A, Grasso F, et al: Oral probiotic administration induces
interleukin-10 production and prevents spontaneous autoimmune diabetes
in the non-obese diabetic mouse. Diabetologia 2005, 48(8):1565–1575.
39. Rasmussen T, Stene LC, Samuelsen SO, Cinek O, Wetlesen T, Torjesen PA,
Ronningen KS: Maternal BMI before pregnancy, maternal weight gain
during pregnancy, and risk of persistent positivity for multiple diabetes-
associated autoantibodies in children with the high-risk HLA genotype:
the MIDIA study. Diabetes Care 2009, 32(10):1904–1906.
40. Bonifacio E, Pfluger M, Marienfeld S, Winkler C, Hummel M, Ziegler AG:
Maternal type 1 diabetes reduces the risk of islet autoantibodies:
relationships with birthweight and maternal HbA(1c). Diabetologia 2008,
51(7):1245–1252.
41. Koczwara K, Bonifacio E, Ziegler AG: Transmission of maternal islet
antibodies and risk of autoimmune diabetes in offspring of mothers
with type 1 diabetes. Diabetes 2004, 53(1):1–4.
42. Elfving M, Lindberg B, Lynch K, Mansson M, Sundkvist G, Lernmark A,
Ivarsson SA: Number of islet autoantibodies present in newly diagnosed
type 1 diabetes children born to non-diabetic mothers is affected by
islet autoantibodies present at birth. Pediatr Diabetes 2008, 9(2):127–134.
43. Lamb MM, Yin X, Zerbe GO, Klingensmith GJ, Dabelea D, Fingerlin TE,
Rewers M, Norris JM: Height growth velocity, islet autoimmunity and type
1 diabetes development: the diabetes autoimmunity study in the young.
Diabetologia 2009, 52(10):2064–2071.
44. Winkler C, Marienfeld S, Zwilling M, Bonifacio E, Ziegler AG: Is islet
autoimmunity related to insulin sensitivity or body weight in children of
parents with type 1 diabetes? Diabetologia 2009, 52(10):2072–2078.
45. Knerr I, Wolf J, Reinehr T, Stachow R, Grabert M, Schober E, Rascher W,
Holl RW: The ‘accelerator hypothesis’: relationship between weight,
height, body mass index and age at diagnosis in a large cohort of 9,248
German and Austrian children with type 1 diabetes mellitus. Diabetologia
2005, 48(12):2501–2504.
46. Clarke SL, Craig ME, Garnett SP, Chan AK, Cowell CT, Cusumano JM,
Kordonouri O, Sambasivan A, Donaghue KC: Increased adiposity at
diagnosis in younger children with type 1 diabetes does not persist.
Diabetes Care 2006, 29(7):1651–1653.
47. Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK: Obesity,
increased linear growth, and risk of type 1 diabetes in children.
Diabetes Care 2000, 23(12):1755–1760.
48. Colman PG, Steele C, Couper JJ, Beresford SJ, Powell T, Kewming K, Pollard
A, Gellert S, Tait B, Honeyman M, et al: Islet autoimmunity in infants with a
type I diabetic relative is common but is frequently restricted to one
autoantibody. Diabetologia 2000, 43(2):203–209.
49. Couper JJ, Steele C, Beresford S, Powell T, McCaul K, Pollard A, Gellert S,
Tait B, Harrison LC, Colman PG: Lack of association between duration of
breast-feeding or introduction of cow’s milk and development of islet
autoimmunity. Diabetes 1999, 48(11):2145–2149.
50. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E: Early infant
feeding and risk of developing type 1 diabetes-associated
autoantibodies. JAMA 2003, 290(13):1721–1728.
51. Virtanen SM, Knip M: Nutritional risk predictors of beta cell autoimmunity
and type 1 diabetes at a young age. Am J Clin Nutr 2003, 78(6):1053–1067.
52. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA,
Rewers M: Timing of initial cereal exposure in infancy and risk of islet
autoimmunity. JAMA 2003, 290(13):1713–1720.
53. Stene LC, Witso E, Torjesen PA, Rasmussen T, Magnus P, Cinek O, Wetlesen T,
Ronningen KS: Islet autoantibody development during follow-up of
high-risk children from the general Norwegian population from three
months of age: design and early results from the MIDIA study. J Autoimmun
2007, 29(1):44–51.
54. Virtanen SM, Kenward MG, Erkkola M, Kautiainen S, Kronberg-Kippila C,
Hakulinen T, Ahonen S, Uusitalo L, Niinisto S, Veijola R, et al: Age at
introduction of new foods and advanced beta cell autoimmunity in
young children with HLA-conferred susceptibility to type 1 diabetes.
Diabetologia 2006, 49(7):1512–1521.
55. Knip M, Virtanen SM, Seppa K, Ilonen J, Savilahti E, Vaarala O, Reunanen A,
Teramo K, Hamalainen AM, Paronen J, et al: Dietary intervention in infancyand later signs of beta-cell autoimmunity. New England Journal of
Medicine 2010, 363(20):1900–1908.
56. Frederiksen B, Kroehl M, Lamb MM, Seifert J, Barriga K, Eisenbarth GS,
Rewers M, Norris JM: Infant exposures and development of type 1
diabetes mellitus: the diabetes autoimmunity study in the young
(DAISY). JAMA Pediatr 2013. doi:10.1001/jamapediatrics.2013.317.
57. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK,
Wabitsch M, O’Brien PE, Harrison LC: Pro-inflammatory CD11c + CD206+
adipose tissue macrophages are associated with insulin resistance in
human obesity. Diabetes 2010, 59(7):1648–1656.
58. Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM,
Cutfield WS: Premature birth and later insulin resistance. New England
Journal of Medicine 2004, 351(21):2179–2186.
59. Petrovsky N, Harrison LC: Diurnal rhythmicity of human cytokine
production: a dynamic disequilibrium in T helper cell type 1/T helper
cell type 2 balance? J Immunol 1997, 158(11):5163–5168.
60. Petrovsky N, Kyvik KO, Bonnevie-Nielsen V, Beck-Nielsen H, Green A,
Harrison LC: Evidence from twins for acquired cellular immune
hyperactivity in type 1 diabetes. Immunology 2002, 106(4):584–589.
61. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d’Annunzio G, Lorini R, Vanelli M,
Ferrannini E: Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in
children with newly diagnosed Type 1 diabetes: a longitudinal study.
Diabet Med 2008, 25(11):1349–1353.
62. Yeung WC, Al-Shabeeb A, Pang CN, Wilkins MR, Catteau J, Howard NJ,
Rawlinson WD, Craig ME: Children with islet autoimmunity and
enterovirus infection demonstrate a distinct cytokine profile. Diabetes
2012, 61(6):1500–1508.
63. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS,
Rewers M: Elevated C-reactive protein levels in the development of type
1 diabetes. Diabetes 2004, 53(10):2569–2573.
64. Mericq V, Piccardo C, Cai W, Chen X, Zhu L, Striker GE, Vlassara H, Uribarri J:
Maternally transmitted and food-derived glycotoxins: a factor preconditioning
the young to diabetes? Diabetes Care 2010, 33(10):2232–2237.
65. Stene LC, Joner G: Use of cod liver oil during the first year of life is
associated with lower risk of childhood-onset type 1 diabetes: a large,
population-based, case–control study. Am J Clin Nutr 2003, 78(6):1128–1134.
66. Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M, Orton HD, Baron
AE, Clare-Salzler M, Chase HP, et al: Omega-3 polyunsaturated fatty acid
intake and islet autoimmunity in children at increased risk for type 1
diabetes. JAMA 2007, 298(12):1420–1428.
67. Bailey R, Cooper JD, Zeitels L, Smyth DJ, Yang JH, Walker NM, Hypponen E,
Dunger DB, Ramos-Lopez E, Badenhoop K, et al: Association of the vitamin
D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007,
56(10):2616–2621.
68. Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K: CYP2R1 (vitamin
D 25-hydroxylase) gene is associated with susceptibility to type 1
diabetes and vitamin D levels in Germans. Diabetes/Metabolism Research
Reviews 2007, 23(8):631–636.
69. Zhang J, Li W, Liu J, Wu W, Ouyang H, Zhang Q, Wang Y, Liu L, Yang R, Liu
X, et al: Polymorphisms in the vitamin D receptor gene and type 1
diabetes mellitus risk: an update by meta-analysis. Mol Cell Endocrinol
2012, 355(1):135–142.
70. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM: Intake of
vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001,
358(9292):1500–1503.
71. Simpson M, Brady H, Yin X, Seifert J, Barriga K, Hoffman M, Bugawan T,
Baron AE, Sokol RJ, Eisenbarth G, et al: No association of vitamin D intake
or 25-hydroxyvitamin D levels in childhood with risk of islet
autoimmunity and type 1 diabetes: the diabetes autoimmunity study in
the young (DAISY). Diabetologia 2011, 54(11):2779–2788.
72. Bowyer L, Catling-Paull C, Diamond T, Homer C, Davis G, Craig ME: Vitamin
D, PTH and calcium levels in pregnant women and their neonates.
Clin Endocrinol (Oxf ) 2009, 70(3):372–377.
73. Zhang Y, Bandala-Sanchez E, Harrison LC: Revisiting regulatory T cells in
type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2012, 19(4):271–278.
74. Bluestone JA, Herold K, Eisenbarth G: Genetics, pathogenesis and clinical
interventions in type 1 diabetes. Nature 2010, 464(7293):1293–1300.
75. Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T, Melville EL,
Peng K, D’Andrea RJ, Glonek GG, et al: Genome-wide identification of human
FOXP3 target genes in natural regulatory T cells. J Immunol 2010,
185(2):1071–1081.
Penno et al. BMC Pediatrics 2013, 13:124 Page 15 of 15
http://www.biomedcentral.com/1471-2431/13/12476. Bandala-Sanchez E, Zhang Y, Reinwald S, Dromey JA, Lee BH, Qian J,
Bohmer RM, Harrison LC: T cell regulation mediated by interaction of
soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol 2013,
14:741–748.
77. Petrovsky N, Harrison LC: Cytokine-based human whole blood assay for
the detection of antigen-reactive T cells. J Immunol Methods 1995,
186(1):37–46.
78. Yeung WC, Rawlinson WD, Craig ME: Enterovirus infection and type 1
diabetes mellitus: systematic review and meta-analysis of observational
molecular studies. Br Med J 2011, 342:d35.
79. Craig ME, Howard NJ, Silink M, Rawlinson WD: Reduced frequency of HLA
DRB1*03-DQB1*02 in children with type 1 diabetes associated with
enterovirus RNA. J Inf Dis 2003, 187(10):1562–1570.
80. Oikarinen S, Martiskainen M, Tauriainen S, Huhtala H, Ilonen J, Veijola R,
Simell O, Knip M, Hyoty H: Enterovirus RNA in blood is linked to the
development of type 1 diabetes. Diabetes 2011, 60(1):276–279.
81. Tapia G, Cinek O, Rasmussen T, Witso E, Grinde B, Stene LC, Ronningen KS:
Human enterovirus RNA in monthly fecal samples and islet
autoimmunity in Norwegian children with high genetic risk for type 1
diabetes: the MIDIA study. Diabetes Care 2011, 34(1):151–155.
82. Stene LC, Oikarinen S, Hyoty H, Barriga KJ, Norris JM, Klingensmith G,
Hutton JC, Erlich HA, Eisenbarth GS, Rewers M: Enterovirus infection and
progression from islet autoimmunity to type 1 diabetes: the diabetes
and autoimmunity study in the young (DAISY). Diabetes 2010,
59(12):3174–3180.
83. Lempainen J, Tauriainen S, Vaarala O, Makela M, Honkanen H, Marttila J,
Veijola R, Simell O, Hyoty H, Knip M, et al: Interaction of enterovirus
infection and cow’s milk-based formula nutrition in type 1 diabetes-
associated autoimmunity. Diabetes Metab Res Rev 2012, 28(2):177–185.
84. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE,
Couper JJ, Tait BD, Colman PG, Harrison LC: Association between rotavirus
infection and pancreatic islet autoimmunity in children at risk of
developing type 1 diabetes. Diabetes 2000, 49(8):1319–1324.
85. Honeyman MC, Stone NL, Falk BA, Nepom G, Harrison LC: Evidence for
molecular mimicry between human T cell epitopes in rotavirus and
pancreatic islet autoantigens. J Immunol 2010, 184(4):2204–2210.
86. Hull B, Dey A, Mahajan D, Menzies R, McIntyre PB: Immunisation coverage
annual report, 2009. Commun Dis Intell 2011, 35(2):132–148.
87. Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM,
Patel MM, Baggs JM, Parashar UD: Burden of acute gastroenteritis
hospitalizations and emergency department visits in US children that is
potentially preventable by rotavirus vaccination: a probe study using the
now-withdrawn rotashield vaccine. Pediatrics 2009, 123(3):744–749.
88. Simell O, Niinikoski H, Ronnemaa T, Raitakari OT, Lagstrom H, Laurinen M,
Aromaa M, Hakala P, Jula A, Jokinen E, et al: Cohort profile: the STRIP study
(Special Turku Coronary Risk Factor Intervention Project), an infancy-
onset dietary and life-style intervention trial. Int J Epidemiol 2009,
38(3):650–655.
89. Oresic M, Gopalacharyulu P, Mykkanen J, Lietzen N, Makinen M, Nygren H,
Simell S, Simell V, Hyoty H, Veijola R, et al: Cord serum lipidome in
prediction of islet autoimmunity and type 1 diabetes. Diabetes 2013: .
doi:10.2337/db13-0159.
90. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, Daunay A,
Busato F, Mein CA, Manfras B, et al: Identification of type 1 diabetes-
associated DNA methylation variable positions that precede disease
diagnosis. PLoS Genet 2011, 7(9):e1002300.
91. Zhang Y, Maksimovic J, Naselli G, Qian J, Blewitt ME, Oshlack A, Harrison LC:
Genome-wide DNA methylation analysis identifies hypomethylated
genes with the forkhead-binding motif in human regulatory T cells.
Blood. in press.
92. Teddy Study Group: The environmental determinants of diabetes in the
young (TEDDY) study: study design. Pediatr Diabetes 2007, 8(5):286–298.
93. Akerblom HK: The trial to reduce IDDM in the genetically at risk (TRIGR)
study: recruitment, intervention and follow-up. Diabetologia 2011,
54(3):627–633.
94. Roll U, Christie MR, Fuchtenbusch M, Payton MA, Hawkes CJ, Ziegler AG:
Perinatal autoimmunity in offspring of diabetic parents. The German
Multicenter BABY-DIAB study: detection of humoral immune responses
to islet antigens in early childhood. Diabetes 1996, 45(7):967–973.
95. Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G: The anti cancer
council of Victoria FFQ: relative validity of nutrient intakes comparedwith weighed food records in young to middle-aged women in a study
of iron supplementation. Aust N Z J Public Health 2000, 24(6):576–583.
96. Chasan-Taber L, Schmidt MD, Roberts DE, Hosmer D, Markenson G,
Freedson PS: Development and validation of a pregnancy physical
activity questionnaire. Med Sci Sports Exerc 2004, 36(10):1750–1760.
97. Johnson RK, Driscoll P, Goran MI: Comparison of multiple-pass 24-hour
recall estimates of energy intake with total energy expenditure
determined by the doubly labeled water method in young children.
J Am Diet Assoc 1996, 96(11):1140–1144.
98. Golley RK, Hendrie GA: The impact of replacing regular- with reduced-fat
dairy foods on children’s wider food intake: secondary analysis of a
cluster RCT. Eur J Clin Nutr 2012, 66(10):1130–1134.
99. Duncanson K, Burrows T, Collins C: Study protocol of a parent-focused
child feeding and dietary intake intervention: the feeding healthy food
to kids randomised controlled trial. BMC Publ Health 2012, 12:564.
100. Australian Bureau of Statistics: Australian Demographic Statistics Tables.
In Australian Demographics Statistics, Dec 2012. Volume 31010DO002_201212.
Edited by Australian Bureau of Statistics. Canberra; 2013.
101. Collett D: Modelling Survival Data in Medical Research. 2nd edition. Florida:
Chapman & Hall/CRC Press LLC; 2003.
102. SocialBaker: Australia Facebook Statistics. [http://www.socialbakers.com/
facebook-statistics/australia]
103. National Health and Medical Research Council 2007: National Statement
on Ethical Conduct in Human Research 2007 - Updated 2009. In NHMRC
Publications. vol. E72. Edited by Australian Government. Canberra; 2007.
104. Colagiuri SBA, Gomez M, Fitzgerald B, Buckley A, Colagiuri R: DiabCo$t
Australia Type 1: Assessing the burden of Type 1 Diabetes in Australia.
Canberra: Diabetes Australia; 2009.
doi:10.1186/1471-2431-13-124
Cite this article as: Penno et al.: Environmental determinants of islet
autoimmunity (ENDIA): a pregnancy to early life cohort study in
children at-risk of type 1 diabetes. BMC Pediatrics 2013 13:124.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
